331729-64-7

Upstream product

• 17564-64-6 N-(chloromethyl)phthalimide 
• 106-48-9 4-chloro-phenol 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 3970-05-6 5-chloro-2-hydroxybenzylamine 

Downstream Products

• 331729-41-0 2-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzyl]isoindole-1,3-dione 
• 331729-40-9 5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzylamine 
• 331728-88-2 3-azido-5-{6-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy) benzylamino]purin-9-yl}-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide 
• 331727-55-0 CP-608039 
• 331729-92-1 2-[5-Chloro-2-(pyridin-3-ylmethoxy)benzyl]isoindole-1,3-dione 
• 519171-97-2 2-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzyl)-isoindole-1,3-dione 

Relevant academic research and scientific papers

3'-aminoadenosine-5'-uronamides: Discovery of the first highly selective agonist at the human adenosine A3 receptor

Selective adenosine A3 agonists have potential utility for the prevention of perioperative myocardial ischemic injury. Herein, we report on the discovery and synthesis of compound 7. This amino nucleoside agonist possesses unprecedented levels

Methods of using piperazine derivatives

The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.